Literature DB >> 10760687

PTEN / MMAC1 mutation and frequent loss of heterozygosity identified in chromosome 10q in a subset of hepatocellular carcinomas.

Y Fujiwara1, D S Hoon, T Yamada, K Umeshita, M Gotoh, M Sakon, I Nishisho, M Monden.   

Abstract

Frequent allelic losses on chromosome 10q have been reported in several types of cancers, suggesting the presence of a putative tumor suppressor gene(s) on the chromosomal arm. We examined loss of heterozygosity (LOH) on chromosome 10q in 37 hepatocellular carcinomas (HCC) using eleven dinucleotide microsatellite markers, spanning the entire chromosome arm of 10q. Twelve (32%) out of 37 informative cases showed allelic losses of at least one locus on 10q and eight tumors showed a partial deletion of 10q. Analysis of deletion mapping of these eight cases identified two commonly deleted regions within the distal part of 10q (10q24-q26), a 20-cM interval flanked by D10S597 and D10S216 and a 24-cM interval flanked by D10S216 and D10S590. Moreover, we detected a somatic missense mutation (Met --> Val) of a candidate tumor suppressor gene PTEN / MMAC1, located at 10q23.3, in one HCC with LOH of 10q. Our findings indicated the presence of putative tumor suppressor gene(s) in the distal region of 10q that might be involved in the development and progression of HCC. Inactivation of PTEN / MMAC1 gene located outside the commonly deleted region of 10q might also play an important role in a subset of HCCs.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10760687      PMCID: PMC5926370          DOI: 10.1111/j.1349-7006.2000.tb00943.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  40 in total

1.  Deletions in human chromosome arms 11p and 13q in primary hepatocellular carcinomas.

Authors:  H P Wang; C E Rogler
Journal:  Cytogenet Cell Genet       Date:  1988

2.  PTEN germ-line mutations in juvenile polyposis coli.

Authors:  S Olschwang; O M Serova-Sinilnikova; G M Lenoir; G Thomas
Journal:  Nat Genet       Date:  1998-01       Impact factor: 38.330

3.  Deletions of the long arm of chromosome 10 in progression of follicular thyroid tumors.

Authors:  J Zedenius; G Wallin; A Svensson; J Bovèe; A Höög; M Bäckdahl; C Larsson
Journal:  Hum Genet       Date:  1996-03       Impact factor: 4.132

4.  Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers.

Authors:  P A Steck; M A Pershouse; S A Jasser; W K Yung; H Lin; A H Ligon; L A Langford; M L Baumgard; T Hattier; T Davis; C Frye; R Hu; B Swedlund; D H Teng; S V Tavtigian
Journal:  Nat Genet       Date:  1997-04       Impact factor: 38.330

5.  PTEN/MMAC1 mutations in endometrial cancers.

Authors:  J I Risinger; A K Hayes; A Berchuck; J C Barrett
Journal:  Cancer Res       Date:  1997-11-01       Impact factor: 12.701

6.  Chromosome 10 allelic loss in malignant melanoma.

Authors:  K Isshiki; D E Elder; D Guerry; A J Linnenbach
Journal:  Genes Chromosomes Cancer       Date:  1993-11       Impact factor: 5.006

7.  Deletion mapping of chromosome 4q in hepatocellular carcinoma.

Authors:  Z Piao; C Park; J H Park; H Kim
Journal:  Int J Cancer       Date:  1998-08-21       Impact factor: 7.396

8.  The lipid phosphatase activity of PTEN is critical for its tumor supressor function.

Authors:  M P Myers; I Pass; I H Batty; J Van der Kaay; J P Stolarov; B A Hemmings; M H Wigler; C P Downes; N K Tonks
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-10       Impact factor: 11.205

9.  Allelotype of breast cancer: cumulative allele losses promote tumor progression in primary breast cancer.

Authors:  T Sato; A Tanigami; K Yamakawa; F Akiyama; F Kasumi; G Sakamoto; Y Nakamura
Journal:  Cancer Res       Date:  1990-11-15       Impact factor: 12.701

10.  Deletion mapping of chromosome 10 in human glioma.

Authors:  Y Sonoda; Y Murakami; T Tominaga; T Kayama; T Yoshimoto; T Sekiya
Journal:  Jpn J Cancer Res       Date:  1996-04
View more
  14 in total

1.  A PTEN inhibitor displays preclinical activity against hepatocarcinoma cells.

Authors:  Giuseppa Augello; Roberto Puleio; Maria Rita Emma; Antonella Cusimano; Guido R Loria; James A McCubrey; Giuseppe Montalto; Melchiorre Cervello
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

2.  PTEN in liver diseases and cancer.

Authors:  Marion Peyrou; Lucie Bourgoin; Michelangelo Foti
Journal:  World J Gastroenterol       Date:  2010-10-07       Impact factor: 5.742

3.  The alteration of PTEN tumor suppressor expression and its association with the histopathological features of human primary hepatocellular carcinoma.

Authors:  X-W Wan; M Jiang; H-F Cao; Y-Q He; S-Q Liu; X-H Qiu; M-C Wu; H-Y Wang
Journal:  J Cancer Res Clin Oncol       Date:  2003-03-07       Impact factor: 4.553

4.  Study of the PTEN gene expression and FAK phosphorylation in human hepatocarcinoma tissues and cell lines.

Authors:  Lineng Zhang; Qiang Yu; Jianyu He; Xiliang Zha
Journal:  Mol Cell Biochem       Date:  2004-07       Impact factor: 3.396

Review 5.  Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging.

Authors:  Linda S Steelman; William H Chappell; Stephen L Abrams; Ruth C Kempf; Jacquelyn Long; Piotr Laidler; Sanja Mijatovic; Danijela Maksimovic-Ivanic; Franca Stivala; Maria C Mazzarino; Marco Donia; Paolo Fagone; Graziella Malaponte; Ferdinando Nicoletti; Massimo Libra; Michele Milella; Agostino Tafuri; Antonio Bonati; Jörg Bäsecke; Lucio Cocco; Camilla Evangelisti; Alberto M Martelli; Giuseppe Montalto; Melchiorre Cervello; James A McCubrey
Journal:  Aging (Albany NY)       Date:  2011-03       Impact factor: 5.682

6.  Expression of PTEN, PPM1A and P-Smad2 in hepatocellular carcinomas and adjacent liver tissues.

Authors:  Shu-Kun Wu; Bao-Ju Wang; Yan Yang; Xin-Hua Feng; Xi-Ping Zhao; Dong-Liang Yang
Journal:  World J Gastroenterol       Date:  2007-09-14       Impact factor: 5.742

7.  PIK3IP1, a negative regulator of PI3K, suppresses the development of hepatocellular carcinoma.

Authors:  Xin He; Zhenqi Zhu; Carla Johnson; John Stoops; Amanda E Eaker; William Bowen; Marie C DeFrances
Journal:  Cancer Res       Date:  2008-07-15       Impact factor: 12.701

Review 8.  Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives.

Authors:  Ying-Chun Shen; Chiun Hsu; Ann-Lii Cheng
Journal:  J Gastroenterol       Date:  2010-06-22       Impact factor: 6.772

Review 9.  Targeted therapy for hepatocellular carcinoma: novel agents on the horizon.

Authors:  Melchiorre Cervello; James A McCubrey; Antonella Cusimano; Nadia Lampiasi; Antonina Azzolina; Giuseppe Montalto
Journal:  Oncotarget       Date:  2012-03

Review 10.  Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.

Authors:  James A McCubrey; Linda S Steelman; William H Chappell; Stephen L Abrams; Giuseppe Montalto; Melchiorre Cervello; Ferdinando Nicoletti; Paolo Fagone; Grazia Malaponte; Maria C Mazzarino; Saverio Candido; Massimo Libra; Jörg Bäsecke; Sanja Mijatovic; Danijela Maksimovic-Ivanic; Michele Milella; Agostino Tafuri; Lucio Cocco; Camilla Evangelisti; Francesca Chiarini; Alberto M Martelli
Journal:  Oncotarget       Date:  2012-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.